HCMHUTCHMED (China) Limited

$3B

Q1 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$82M+58.1% YoY

Gross Profit

$17M20.4% margin

Operating Income

-$63M-77.5% margin

Net Income

-$65M-79.5% margin

EPS (Diluted)

$-0.45

QoQ Revenue Growth

+34.6%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$29M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$693M

Total Liabilities

$229M

Stockholders' Equity

$428M

Cash & Equivalents

$346M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$82M	$52M	+58.1%
Gross Profit	$17M	$10M	+61.6%
Operating Income	-$63M	-$32M	-94.5%
Net Income	-$65M	-$16M	-301.7%

HCM Q1 2021 Earnings — HUTCHMED (China) Limited Revenue & Financial Results | Market Cap Arena